The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Projections from real world evidence of CLL management
Although major developments are being made in the treatment of chronic lymphocytic leukemia (CLL), in many settings in the real world these novel therapies are not available. Here, Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, discusses projections from real world evidence on the landscape of CLL management, including the cost of drugs, differing healthcare systems in between countries, the age and life expectancy of patients, and more. This interview took place at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
